Please try another search
As of December 15, 2016, Bionor Pharma ASA was acquired by Solon Eiendom AS in a reverse merger transaction. Bionor Pharma ASA, a biotechnology company, engages in the development of vaccines for viral diseases. It focuses on developing a therapeutic vaccine Vacc-4x, a human immunodeficiency virus (HIV) vaccine candidate, which is in clinical trials for reducing viral load and killing virus producing cells. The company also engages in developing Vacc-C5, a peptide designed to induce antibody responses to the HIV gp120 C5 domain; and Vacc-FLU, a preclinical phase influenza vaccine. In addition, it offers nutraceutical products, such as Nutri5 and NutriPro. The company operates in Norway, Europe, and Russia. The company was formerly known as Nutri Pharma ASA and changed its name to Bionor Pharma ASA in June 2010. Bionor Pharma ASA was founded in 1993 and is headquartered in Oslo, Norway.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review